Asker Healthcare Group AB

STO-ASKER
Nasdaq Stockholm
Healthcare Medical, Dental, and Hospital Equipment and Supplies
Global Rank
#4642
Country Rank
#55
Market Cap
3.67 B
Price
8.55
Change (%)
2.02%
Volume
359,795

Asker Healthcare Group AB's latest marketcap:

3.67 B

As of 07/21/2026, Asker Healthcare Group AB's market capitalization has reached $3.67 B. According to our data, Asker Healthcare Group AB is the 4642th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 3.67 B
Revenue (ttm) 1.79 B
Net Income (ttm) 64.66 M
Shares Out 383.04 M
EPS (ttm) 0.17
Forward PE 27.41
Ex-Dividend Date 05/08/2026
Earnings Date 07/21/2026
Market Cap Chart
Data Updated: 07/21/2026

Asker Healthcare Group AB's yearly market capitalization.

Asker Healthcare Group AB has seen its market value grow from kr32.33 B to kr35.63 B since 2025, representing a total increase of 10.20% and an annual compound growth rate (CAGR) of 19.05%.
Date Market Cap(kr) Market Cap(USD) Change (%) Global Rank
07/21/2026 kr35.63 B $3.67 B -10.43% 4642
12/30/2025 kr32.33 B $3.42 B 3474

Company Profile

Asker Healthcare Group AB provides medical supplies, devices, and equipment, and related solutions that support patient care.

It offers protective products, infusion products, and dressings; measuring instruments for diabetes and blood pressure; and endoscopy equipment, incubators, and ventilators, as well as pharmaceuticals.

The company also provides, supplies, and distributes fittings and equipment; veterinary equipment; surgical and diagnostic instruments; medical supplies and equipment for urology, ultrasound diagnostics, laser treatment, and regenerative medicine; medical equipment for operating rooms, polyclinics, and day surgeries; hygiene equipment; equipment and products for beauty clinics; defibrillators and wound care products; and health-related protection and trauma products for emergency care, police service, and military.

In addition, it offers develops and sells disposable medical supplies under the Evercare, Selefa, and Embra brands; distributes eye surgery products; and develops and sells products for time-management, communication, and cognition for schools, assistive technology centres, and other public services.

Further, the company provides support and assistance to people needing wound, diabetes, and urological care; ostomy, urology, and rehab services; ambulance services; products for physiotherapy practices; supplies exercise and treatment equipment and measurement; and sells and rents out various mobility aids and rehab products, such as pressure-relieving mattresses and cushions, as well as manufactures and distributes pressure care products.

The company operates in Sweden, Norway, Finland, Estonia, Latvia, Lithuania, Netherlands, Belgium, Luxembourg, Denmark, the United Kingdom, Ireland, Germany, Austria, Switzerland, Czech Republic, and Poland.

Asker Healthcare Group AB was founded in 2018 and is based in Danderyd, Sweden.

Frequently Asked Questions

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Research Tools

Copyright © 2026. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.